Bionpharma Inc.
Bionpharma Inc. appears in FDA public data with 4 recalls — including 1 Class I (most serious) —, 0 510(k) clearances, 2 FDA inspections, and 0 compliance actions on record. Its most recent recall (D-0822-2026, Class III) was initiated on Aug 7, 2026. Its most recent FDA inspection ended on Sep 19, 2024 (No Action Indicated (NAI)).
Reviewing Bionpharma Inc. as a supplier? Get its full FDA risk summary, with inspections, warning letters, Form 483s and import alerts by site, in Claude, Cursor or ChatGPT.
Summary
- Total Recalls
- 4 (1 Class I)
- 510(k) Clearances
- 0
- Inspections
- 2
- Compliance Actions
- 0
Known Names
Bionpharma, Bionpharma Inc
Recent Recalls
| Number | Class | Product | Date |
|---|---|---|---|
| D-0822-2026 | Class III | Doxylamine Succinate and Pyridoxine HCl Delayed-Release tablets 10 mg/10 mg, 100-count bottle, Rx On | Aug 7, 2026 |
| D-0742-2026 | Class II | Divalproex Sodium Delayed-Release Tablets, USP, 500 mg, 500 Tablets bottles, Rx only, Distributed by | Jun 26, 2026 |
| D-0012-2025 | Class I | Atovaquone Oral Suspension, USP 750 mg/5 mL, 210 mL bottle, Rx only, Distributed by: Bionpharma Inc. | Sep 17, 2024 |
| D-1519-2019 | Class II | Clobazam Oral Suspension, 2.5 mg/mL, 120 mL bottle, Rx only, Distributed by: Bionpharma Inc., 600 Al | Jul 16, 2019 |
Recent FDA Inspections
| Date | Site | Product | Classification | FEI |
|---|---|---|---|---|
| Sep 19, 2024 | Princeton, NJ | Drugs | No Action Indicated (NAI) | 3011705836 |
| Jun 26, 2017 | Princeton, NJ | Drugs | No Action Indicated (NAI) | 3011705836 |